Viridian Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: GlobeNewswire
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Viridian Therapeutics, Inc. (NASDAQ: VRDN). The investigation focuses on Viridian’s executive officers and whether investor losses may be recovered under federal securities laws. What if I purchased Viridian securities?If you purchased Viridian securities and suffered losses on your investment, join our investigation now: Click here to join the investigation. Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471. There is no cost or obligation to you. Background of the investigationOn March 30, 2026, Viridian announced topline results from its REVEAL-1 Phase 3 clinical trial. Among other things, the Company reported that the trial met its primary endpoint with high statistical significance. Viridian disclosed proptosis responder rates of approximately 54% for the every-four-week (Q4W) dosing cohort and approximately 63% for
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Viridian Therapeutics (VRDN) had its price target lowered by The Goldman Sachs Group, Inc. from $41.00 to $36.00. They now have a "buy" rating on the stock.MarketBeat
- Viridian Therapeutics (VRDN) had its price target lowered by Wells Fargo & Company from $29.00 to $20.00. They now have an "equal weight" rating on the stock.MarketBeat
- Viridian Therapeutics (VRDN) had its price target lowered by Wedbush from $44.00 to $37.00. They now have an "outperform" rating on the stock.MarketBeat
- Viridian Therapeutics (VRDN) had its price target lowered by HC Wainwright from $34.00 to $22.00. They now have a "buy" rating on the stock.MarketBeat
- Viridian Therapeutics (VRDN) had its price target lowered by Needham & Company LLC from $42.00 to $32.00. They now have a "buy" rating on the stock.MarketBeat
VRDN
Earnings
- 2/26/26 - Miss
VRDN
Sec Filings
- 3/30/26 - Form 8-K
- 3/27/26 - Form SCHEDULE
- 3/9/26 - Form 4/A
- VRDN's page on the SEC website